BPMC Research and Charts

BPMC - Blueprint Medicines Corp (Healthcare: Biotechnology)

Projected Earnings Date: 2025-07-31 (Delayed quote data 2025-05-09)

Last 97.17	Change ⇓ -1.59 (-1.61%)	Volume 621,844
	Open 98.76	High 101.34	Low 97.08

8EMA (Daily) 97.22	40EMA (Daily) 91.34	50EMA (Daily) 91.40	STO (Daily) 76.288	MACD Hist (Daily) 2.138
8EMA (Weekly) 92.229	40EMA (Weekly) 92.66	50EMA (Weekly) 91.88	STO (Weekly) 39.150	MACD Hist (Weekly) 1.273


Company Profile
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.